Italy Insulin Delivery Devices Market Overview, 2028

Italy has a high prevalence of diabetes, necessitating a healthy market for insulin delivery devices. As of the prevalence of both type 1 and type 2 diabetes, there is a high demand for efficient and diversified insulin administration options. Italy has demonstrated a strong proclivity for implementing breakthrough healthcare technologies. This trend is also evident in insulin delivery devices, where there is a growing interest in cutting-edge technologies such as closed-loop systems (artificial pancreas) and hybrid closed-loop insulin delivery systems. These cutting-edge technologies are designed to enable more automatic and precise insulin delivery, hence improving glycemic control. Telemedicine and remote monitoring are important components of the Italian healthcare scene, particularly diabetes management. Insulin delivery systems that offer remote monitoring or communication with telemedicine platforms allow healthcare practitioners to assess patient data and provide timely interventions or adjustments in treatment plans. The insulin delivery device industry is influenced by Italy's developing healthcare reforms and public health efforts. The country is still looking into ways to improve diabetes care, including increasing access to advanced devices, funding research, and promoting collaborations for improved patient results. With an ageing population, Italy is facing demographic upheavals. As diabetes prevalence rises with age, there is an increasing demand for effective diabetes management options, such as insulin delivery devices, to meet the unique demands of older people. In Italy, efforts are being made to connect healthcare systems and increase interoperability between devices and electronic health records (EHRs). Insulin delivery devices that interact smoothly with existing healthcare infrastructure and EHR systems are recognised for their capacity to simplify data sharing and improve the continuity of treatment.

According to the research report "Italy Insulin Delivery Devices Market Overview, 2028," published by Bonafide Research, the Italy Insulin Delivery Devices market is predicted to add more than USD 250 Million from 2023 to 2028. Italy has made investments in diabetes prevention and early intervention programmes. The insulin delivery devices primarily serve people who have been diagnosed with diabetes, the country is increasingly emphasising prevention and early diagnosis. This strategy attempts to minimise the total diabetes burden, potentially influencing the long-term need for insulin delivery devices. Collaborations between pharmaceutical companies and insulin delivery device makers are common in Italy. These collaborations frequently focus on developing unique insulin formulations that are compatible with certain device technology, with the goal of improving patient efficacy, stability, and convenience of delivery. Precision medicine is becoming more important in Italy's healthcare sector. In diabetes care, this translates into personalised treatment strategies that take into account unique patient characteristics. Insulin delivery systems contribute to this trend by providing customised features that suit patient’s specific needs and preferences. Diabetes awareness and activism are becoming more prominent in Italy. Patient advocacy groups and organisations seek to improve awareness, decrease stigma, and encourage access to appropriate diabetes management technologies, such as insulin delivery devices, while also campaigning for greater resources and support for individuals living with diabetes. Italy adheres to recognised clinical recommendations and best practices for diabetes management. These guidelines frequently propose insulin therapy as a critical component for glycemic control in specific patient populations, influencing the use and uptake of insulin delivery devices. Italy, like many other countries, is interested in minimally invasive technologies. Manufacturers are investigating novel approaches to insulin delivery that minimise discomfort and promote less intrusive procedures, which could influence future device designs and adoption rates.

In terms of product market in bifurcated into insulin pens, insulin pumps, insulin pen needles, insulin syringes and others insulin delivery devices (insulin transdermal patches, insulin inhalers, insulin jet injection). Among them insulin pumps product is expected to grow at significant pace in Italy insulin delivery devices market. Insulin pump technology is evolving, with features such as automated insulin delivery, integration with continuous glucose monitoring (CGM) systems, improved user interfaces, and smaller form factors becoming available. These advancements improve insulin pump performance, accuracy, and user experience, making them more desirable to patients and healthcare providers. Insulin pumps provide accurate modifications to basal rates and bolus dosages by allowing for highly customised insulin delivery profiles. This dose flexibility corresponds to individualised treatment demands, particularly for patients with changing insulin requirements throughout the day, such as those with type 1 diabetes. Closed-loop systems, also known as hybrid closed-loop or artificial pancreas systems are formed by the integration of insulin pumps and CGM devices. This interface enables automated insulin delivery modifications based on real-time glucose measurements, enhancing precision and reducing the burden of constant glucose monitoring and manual insulin adjustments.

Based on end user segment market is segmented into home care, hospitals and clinics and others. Hospitals and clinics end user segment is expected to grow at rapid pace in Italy insulin delivery devices market. Diabetes care is becoming increasingly important in hospitals and clinics. They are combining modern technologies, such as insulin delivery devices, to improve diabetes treatment outcomes. In order to improve patient outcomes, healthcare facilities pursue sophisticated treatment approaches. Insulin delivery devices, particularly pumps and integrated systems, are responding to this demand by providing more complex and precise insulin administration alternatives in clinical settings. Diabetes is managed in hospitals in inpatient settings, which necessitates accurate insulin dose and management. Insulin pumps and sophisticated delivery systems are critical in providing continuous and accurate insulin delivery to hospitalised patients, guaranteeing optimal glycemic control during their stay. The indication segment of the market includes diabetes, pregnancy, cardiovascular disorders & hypertension, respiratory diseases, hearing disorders, cancer, movement disorders, wound care and other indications (sleep disorders, kidney disorders, neurovascular diseases, and HIV). Among them diabetes indication is major consumer of insulin delivery devices in Italy. Diabetes is a significant public health issue in Italy. According to the International Diabetes Federation (IDF), approximately 3 million individuals in Italy have diabetes, Diabetes is classified into two types: type 1 diabetes and type 2 diabetes. Type 1 diabetes is an autoimmune illness in which the body attacks and destroys insulin-producing cells. The most prevalent kind of diabetes is type 2 diabetes, which is frequently caused by lifestyle factors such as obesity and a lack of exercise.

Considered in this report:
• Geography: Italy
• Historic year: 2017
• Base year: 2022
• Estimated year: 2023
• Forecast year: 2028



Aspects covered in this report:
• Italy Insulin Delivery Devices market with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

By Product:
• Insulin Pens
• Insulin Pumps
• Insulin Pen Needles
• Insulin Syringes
• Others Insulin Delivery Devices(Insulin transdermal patches, Insulin inhalers, Insulin jet injection)

By End User:
• Home Care
• Hospitals & Clinics
• Others

By Indication:
• Diabetes
• Pregnancy
• Cardiovascular Disorders & Hypertension
• Respiratory Diseases
• Hearing Disorders
• Cancer
• Movement Disorders
• Wound Care
• Other Indications (sleep disorders, kidney disorders, neurovascular diseases, and HIV)

The approach of the report:
This report consists of a combined approach of primary as well as secondary research. Initially, secondary research was used to get an understanding of the market and list out the companies that are present in the market. The secondary research consists of third-party sources such as press releases, and annual reports of companies, analyzing the government-generated reports and databases. After gathering the data from secondary sources primary research was conducted by making telephonic interviews with the leading players about how the market is functioning and then conducting trade calls with dealers and distributors of the market. Post this we have started doing primary calls to consumers by equally segmenting consumers into regional aspects, tier aspects, age groups, and gender. Once we have primary data with us we started verifying the details obtained from secondary sources.

Intended audience:
This report can be useful to industry consultants, manufacturers, suppliers, associations & organizations related to the Insulin Delivery Devices industry, government bodies, and other stakeholders to align their market-centric strategies. In addition to marketing & presentations, it will also increase competitive knowledge about the industry.